This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis' Applications for MS Drug Accepted by FDA & EMA
by Zacks Equity Research
Novartis (NVS) progresses with its MS candidate, siponimod, as both the FDA and the EMA accepts the applications for the drug.
Roche (RHHBY) Presents Encouraging Data on SMA Drug Risdiplam
by Zacks Equity Research
Roche (RHHBY) reports encouraging data from two pivotal studies -- FIREFISH and SUNFISH -- on risdiplam for the treatment of Spinal Muscular Atrophy.
3 Biotech Stocks With Rising Estimates in the Past Month
by Zacks Equity Research
The biotech industry is performing reasonably well. Hence, it is a good idea to select stocks from the sector witnessing positive estimate revisions.
3 Drug/Biotech Stocks in Focus on World Alzheimer's Day
by Zacks Equity Research
We take a look at companies with prospective Alzheimer's Disease candidates in pipeline on World Alzheimer's Day.
The Zacks Analyst Blog Highlights: Wells Fargo, Schlumberger, Biogen, American Express and Illinois Tool Works
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Wells Fargo, Schlumberger, Biogen, American Express and Illinois Tool Works
Top Research Reports for Wells Fargo, Schlumberger & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), Schlumberger (SLB) and Biogen (BIIB).
Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija
by Zacks Equity Research
The FDA defers decision by three months regarding the NDA of Acorda's (ACOR) Parkinson's disease candidate Inbrija for the treatment of OFF periods.
Alkermes Expands Study to Evaluate ALKS 4230-Keytruda Combo
by Zacks Equity Research
Alkermes expands a phase I study to evaluate its immuno-oncology candidate, ALKS 4230, in combination with Keytruda in patients with advanced solid tumors.
Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down
by Zacks Equity Research
Acorda Therapeutics' (ACOR) stock slumps after a Federal Circuit Court rules against its appeal to protect patents pertaining to its key multiple sclerosis drug, Ampyra
Biogen Begins Phase III Study on Ischemic Stroke Candidate
by Zacks Equity Research
Biogen (BIIB) enrolls first patient in a phase III study evaluating BIIB093 for prevention and treatment of severe cerebral edema in large hemispheric infarction.
Biogen (BIIB) Down 10.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Biogen (BIIB) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.
Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FLQL
Lilly (LLY) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Biogen (BIIB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BIIB) Outperforming Other Medical Stocks This Year?
Has Biogen (BIIB) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (BIIB) Outperforming Other Medical Stocks This Year?
Pain Therapeutics' Shares Rally on Alzheimer's Study Grant
by Zacks Equity Research
Pain Therapeutics (PTIE) receives grant of $3.2 million from National Institutes of Health to support development of its Alzheimer's disease candidate, PTI-125.
Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children
by Zacks Equity Research
Vertex's (VRTX) cystic fibrosis drug, Kalydeco gets FDA approval to treat children aged 12 months to two years
Biotech ETFs in Focus on String of Q2 Earnings Beat
by Sanghamitra Saha
Biotech ETFs draw attention post impressive Q2 results.
PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings trump estimates in Q2. Lower royalties and license fees cause a significant decline in year-over-year revenues.
S&P 500 Posts 5th Straight Weekly Gain: 5 Great Picks
by Nalak Das
U.S. corporates have so far posted robust results for second-quarter 2018, maintaining the terrific earnings momentum which has begun since the first-quarter 2018.
Zacks.com featured highlights include: Biogen, Thermo Fisher, HCA, Gilead and QUALCOMM
by Zacks Equity Research
Zacks.com featured highlights include: Biogen, Thermo Fisher, HCA, Gilead and QUALCOMM
5 Cheap PEG Stocks Suitable for GARP Investors
by Zacks Equity Research
Although PEG is categorized under value investing, this strategy follows the principles of both growth and value investing.
Is a Beat in Store for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
On Ionis' (IONS) second-quarter 2018 conference call, investor focus will remain on the company's progress with the pipeline candidates as well as royalty revenues earned from Spinraza.
Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q2, Gilead's CEO to Exit
by Zacks Equity Research
Impressive second-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.
The Zacks Analyst Blog Highlights: Comcast, United Technologies, Biogen, Mondelez and Valero
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Comcast, United Technologies, Biogen, Mondelez and Valero